The Government of Japan has granted additional funding to the Global Antibiotic Research and Development Partnership (GARDP) to support its vital work in developing new … Funding from Government of Japan will boost GARDP’s work in developing new treatments
People around the world are set to benefit from £4.5 million investment from UK Government to develop innovative treatments for drug-resistant infections which cost millions of lives every year.
Osaka (Japan), Geneva (Switzerland), Boston (USA), 15 June 2022 – Shionogi & Co., Ltd. (Shionogi) and the Global Antibiotic Research and Development Partnership (GARDP) have … Shionogi, GARDP and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries
The Global Antibiotic Research and Development Partnership (GARDP) and Bugworks, a key player in the global antimicrobial resistance (AMR) innovation ecosystem, are collaborating on a … GARDP supports Bugworks in assessing safety of new antibiotic compound
A large study focusing on newborn babies with clinically diagnosed sepsis has revealed the impact of antibiotic resistance on neonatal sepsis, a major cause of death in newborns.
The Global Antibiotic Research and Development Partnership (GARDP) welcomes funding from the Australian Government to support its critical work in developing and delivering treatments for … GARDP welcomes funding from the Australian Government to boost its critical work to tackle drug-resistant infections
Venatorx Pharmaceuticals, Inc., a GARDP collaborator, today announced positive results from its pivotal phase 3 study evaluating cefepime-taniborbactam as a treatment for hospitalized adult patients … GARDP welcomes positive results in Venatorx phase 3 clinical trial of new treatment for serious bacterial infections
Results from a clinical trial completed in Kenya have determined that a safe dose of the antibiotic, fosfomycin, can be used to treat babies with … Potentially life-saving treatment is safe to use for babies with neonatal sepsis, study reveals
GARDP is pleased to announce funding from the Canton of Geneva to support the development of zoliflodacin, a novel antibiotic currently being assessed through a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.
GARDP and the Department of Disease Control of the Thailand Ministry of Public Health (Thai DDC) have signed a Memorandum of Understanding (MOU) to explore opportunities to improve gonorrhea treatment in Thailand, with the intention to develop an access and stewardship strategy to ensure future antibiotics will be available as early as possible in the country.